Global Disease Burden From Acute Glomerulonephritis 1990–2019

In the context of the population growing and aging worldwide, the incidence of non-rheumatic valvular heart disease increased rapidly. This study aimed to describe the burden of non-rheumatic valvular heart disease, providing an up-to-date and comprehensive analysis on the global and regional levels and time trends from 1900 to 2019. The Global Burden of Disease 2019 was used to obtain data for this analysis. Non-rheumatic valvular heart disease in the Global Burden of Disease study includes both non-rheumatic calcific aortic valve disease and non-rheumatic degenerative mitral valve disease. The incidence, mortality, and disability-adjusted life year in 204 countries from 1990 to 2019 were analyzed by location, year, sex, age, and socio-demographic index. Estimated annual percentage change was calculated to represent the temporal trends from 1990 to 2019. Spearman's rank order correlation was used to determine the correlation between socio-demographic index and the incidence and burden of non-rheumatic valvular heart disease. Globally, there were 1.65 million (95% uncertainty interval, 1.56-1.76 million) incident cases, 0.16 million (95% uncertainty interval, 0.14-0.18 million) death cases, and 2.79 million (95% uncertainty interval, 2.52-3.31 million) disability-adjusted life years of non-rheumatic valvular heart disease. Compared with 1990, the number of incident cases, death cases, and disability-adjusted life years in 2019 increased by 104.58%, 210.60%, and 167.62%, respectively, the age-standardized incidence rate (estimated annual percentage change, 0.39; 95% confidence interval, 0.29 to 0.49) increased due to population growth, and the age-standardized death rates (estimated annual percentage change, -0.32; 95% confidence interval, -0.39 to -0.25) and age-standardized disability-adjusted life year rate (estimated annual percentage change, -0.81; 95% confidence interval, -0.87 to -0.74) decreased during this period. Regarding the socio-demographic index, the highest age-standardized incidence, death, and disability-adjusted life year rates of non-rheumatic valvular heart disease were found in high-socio-demographic index countries in 2019. Meantime, the age-standardized incidence rate remained increased from 1990 to 2019, while significant decreases were found in the age-standardized death rate and age-standardized disability-adjusted life year rate. Females have higher age-standardized incidence rate, while higher age-standardized death rate and age-standardized disability-adjusted life year rate belong to males globally during the period of 1990-2019. Increasing trends were observed for both incidence, death, and disability-adjusted life year rates with age. High systolic blood pressure was the leading cause for non-rheumatic valvular heart disease across all ages. From 1990 to 2019, the age-standardized incidence rate of non-rheumatic valvular heart disease remained increased, while age-standardized death rate and age-standardized disability-adjusted life year rate decreased, resulting from the growing population worldwide and improving medical resources. The aged, who has high systolic blood pressure and diet high in sodium, should pay more attention to, especially in high-socio-demographic index regions. With the population aging, the number of patients who require heart valve replacement is estimated to increase significantly in the future. Effective measures are warranted to control and treat the incidence and burden of non-rheumatic valvular heart disease.

Background Ischemic heart disease (IHD) continues to be the foremost contributor to global morbidity and mortality. Few studies have comprehensively analysed IHD burden and its attributable risk factors at global, regional, and national levels using the Global Burden of Disease Study 2021 (GBD 2021) database. Therefore, updated information on the burden of IHD is essential for public health and advocacy purposes. Purpose To report the prevalence, deaths, and disability-adjusted life years (DALYs) due to IHD and its attributable risk factors in 204 countries and territories from 1990 to 2021, by age, sex, and sociodemographic index (SDI). Methods This study used data from the GBD 2021 database. IHD was defined as acute myocardial infarction, chronic stable angina, chronic IHD, and heart failure due to IHD. Cause of death ensemble modelling (CODEm) was used to model deaths from IHD. The nonfatal estimation of IHD burden was modeled using DisMod-MR 2.1 ,a Bayesian meta-regression tool for disease modeling. All estimates were reported as absolute counts and age-standardised rates (ASRs) per 100,000 population, along with their 95% uncertainty intervals (UIs). Pearson's correlation test was used to analyse the correlation between ASRs and SDI. Results Globally, IHD accounted for 254.3 (221.4,295.5) million prevalent cases, 9.0 (8.3,9.5) million deaths and 188.4 (177.0,198.1) million DALYs in 2021. There was a noticeable decline in the global age-standardised death rate (ASDR) [-31.6% (-34.9,-28.3)] and age-standardised DALYs (ASRDALYs) [-28.8% (-32.5,-25.2)] from 1990 to 2021, with an estimated annual percentage change (EAPC) of -1.3 and -1.2, respectively. However, the age-standardised prevalence rate (ASPR) remained steady during the same period, with an EAPC of 0. Comprehensive data on the burden of IHD across 204 countries and territories were presented using detailed tables. In 2021, the global prevalence, death, and DALY rates of IHD were higher among males across all age groups, while death and DALY rates reaching a peak in the oldest group for both sexes. Regionally, we found a nonlinear but negative association between ASPR and SDI (Figure 1). Nationally, similar negative associations were observed between ASDR and SDI, as well as between ASRDALYs and SDI (Figure 2). Globally, high systolic blood pressure and high low-density lipoprotein cholesterol were the factors contributing most to the death and DALY rates of IHD. Other major risk factors included smoking, high fasting plasma glucose, air pollution, impaired kidney function, high body-mass index and diet low in whole grains. Conclusion Despite declining global age-standardised death and DALY rates for IHD, sustained multilevel prevention strategies remain essential. This requires population-wide risk factor reduction, targeted interventions for high-risk populations, and strengthened community healthcare networks to ensure accessible, guideline-based management.Figure1.ASRs and SDI, regional level Fugure2. ASRs and SDI, national level

Analysis of global prevalence, DALY and trends of inflammatory bowel disease and their correlations with sociodemographic index: Data from 1990 to 2019

Ischemic heart disease (IHD) continues to be the foremost contributor to global morbidity and mortality. This analysis aims to report an updated assessment of prevalence, deaths, and disability-adjusted life years (DALYs) due to IHD and its attributable risk factors in 204 countries and territories from 1990 to 2021, by age, sex, and socio-demographic index (SDI). This analysis used data from the Global Burden of Diseases, Injuries, and Risk Factors Study 2021. IHD was defined as acute myocardial infarction, chronic stable angina, chronic IHD, and heart failure due to IHD. Major indicators used in this study were prevalence, death and DALYs. All estimates were reported as absolute counts and age-standardized rates per 100,000 population, along with their 95% uncertainty intervals (UIs). Globally, IHD accounted for 254.3 (95%UI: 221.4 to 295.5) million prevalent cases, 9.0 (95%UI: 8.3 to 9.5) million deaths and 188.4 (95%UI: 177.0 to 198.1) million DALYs in 2021. There was a noticeable decline in the global age-standardized death rate (ASDR) [-31.6% (95%UI: -34.9 to -28.3)] and age-standardized DALYs (ASRDALYs) [-28.8% (95%UI: -32.5 to -25.2)] from 1990 to 2021, with an estimated annual percentage change of -1.3 (95%CI: -1.34 to -1.26) and - 1.2 (95%CI: -1.25 to -1.16), respectively. In 2021, the global prevalence, death, and DALY rates of IHD were higher among males across all age groups, while death and DALY rates reaching a peak in the oldest group for both sexes. Regionally, we found a nonlinear but negative association between age-standardized prevalence rate (ASPR) and SDI. Nationally, similar negative associations were observed between ASRDALYs and SDI. High systolic blood pressure and high low-density lipoprotein cholesterol were the factors contributing most to the deaths and DALYs due to IHD. Despite declining global age-standardized death and DALYs rates of IHD, sustained multilevel prevention strategies remain essential. This requires population-wide risk factor reduction, targeted interventions for high-risk populations, and strengthened community healthcare networks to ensure accessible, guideline-based management.

BackgroundMigraine is a common neurological disorder that has become an increasingly significant public health issue. This study aims to analyze the burden of migraine in China and globally from 1990 to 2021, exploring epidemiological trends and differences, thus providing scientific evidence for migraine prevention and control.MethodsBased on the 2021 Global Burden of Disease (GBD) study, we assessed migraine burden in China and globally from 1990 to 2021 using indicators including incidence, prevalence, disability-adjusted life years (DALYs), and age-standardized rates. The epidemiological trends were analyzed by calculating the estimated annual percentage change (EAPC). Health inequality analysis was conducted to explore the association between migraine burden and the sociodemographic index (SDI). Decomposition analysis quantified contributions of age structure, population growth, and epidemiological changes to migraine burden. Additionally, the Bayesian Age-Period-Cohort (BAPC) model was applied to predict migraine burden in China and globally over the next 10 years.ResultsCompared with 1990, the number of migraine cases, prevalence, and DALYs in both China and globally significantly increased by 2021, though the global growth rate was considerably higher. Between 1990 and 2021, China experienced greater increases in age-standardized incidence rates (ASIR), age-standardized prevalence rates (ASPR), and age-standardized DALYs rates (ASDR) than the global average. Migraine burden was predominantly concentrated among adolescents and young adults, and females consistently exhibited a higher burden than males. Health inequality analysis revealed increasing disparity across 204 countries and regions, with a concentrated migraine burden in high socio-demographic index (SDI) countries, positively correlated with SDI. Decomposition analysis indicated that population growth was the primary driver of migraine burden changes in both China and globally. BAPC modeling predicted that the age-standardized incidence, prevalence, and DALY rates for migraine will continue to rise in China, whereas these rates are expected to slightly decline globally.ConclusionsMigraine burden is rising in both China and globally, driven by multiple factors such as age, gender, population growth, and SDI. There is an urgent need for precise interventions to reduce migraine's public health impact.

Global burden and risk factors of musculoskeletal disorders among adolescents and young adults in 204 countries and territories, 1990–2019

BackgroundPulmonary arterial hypertension (PAH) is a severe and progressive lung disease that significantly impairs patients’ health and imposes heavy clinical and economic burdens. Currently, there is a lack of comprehensive epidemiological analysis on the global burden and trends of PAH.MethodsWe estimated the prevalence, mortality, disability-adjusted life years (DALYs) of PAH from 1990 to 2021 using the results of the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD). The average annual percentage changes were used to estimate the trends of PAH across 21 regions and 204 countries and territories.ResultsFrom 1990 to 2021, the number of prevalent cases and deaths associated with PAH worldwide increased by 81.5 and 48.4%. However, the age-standardized prevalence rate of PAH remained relatively stable, while the age-standardized mortality rate and DALYs declined. In 2021, the global age-standardized prevalence rate of PAH was 2.28 per 100,000, with 1.78 per 100,000 in males and 2.75 per 100,000 in females. The age-standardized mortality rate of PAH globally was 0.27 per 100,000, and the age-standardized DALYs was 8.24 per 100,000. Among the 21 regions, Western Europe had the highest age-standardized prevalence rate (3.56 per 100,000), while North Africa and the Middle East had the highest age-standardized mortality rate (0.44 per 100,000) and DALYs (14.81 per 100,000). Additionally, older individuals and females are at higher risk of PAH. The age-standardized mortality rate and DALYs associated with PAH increase with age, peaking in the 95+ age group. As the sociodemographic index increased, the age-standardized prevalence rates showed an upward trend, while both the age-standardized mortality rates and DALYs exhibited a downward trend.ConclusionFrom 1990 to 2021, the overall trend of PAH burden presents regional and national variations and differs by age, sex, and sociodemographic index. These findings emphasize the importance of implementing targeted interventions to alleviate the burden of PAH.

ObjectivesTo provide the level and trends of prevalence, incidence and disability adjusted life years (DALYs) for rheumatoid arthritis (RA) in 195 countries from 1990 to 2017 by age, sex, Socio-demographic...

Global burden of non-rheumatic valvular heart disease in older adults (60-89 years old), 1990-2019: systematic analysis of the Global Burden of Disease Study 2019

BackgroundYoung chronic obstructive pulmonary disease (COPD) refers to people with COPD between the ages of 20 and 50 years. Current epidemiological studies focus on local geography, and there is a lack of global-level analysis. This study provides in-depth analyses of the disease burden of young COPD at global, regional, and national levels.MethodsThis study used the Global Burden of Disease Study 2021 (GBD). The age-standardised prevalence rate (ASPR), age-standardised incidence rate (ASIR), age-standardised death rate (ASDR), and age-standardised disability-adjusted life years (DALYs) rate were used to describe the disease burden. The estimated annual percentage change (EAPC) during the study period was calculated. Joinpoint regression analysis examined the time trend from 1990 to 2021. Annual percentage change (APC) and average annual percentage change (AAPC) were calculated. Risk factors were reported by region and sex.ResultsIn 2021, the global number of young COPD cases was 30,384,539, and the ASPR, ASIR, ASDR, and age-standardised DALYs rates fell slightly. Oceania reported the highest ASPR, ASDR, and age-standardised DALYs rate. High-income North America has the highest ASIR. In 2021, the prevalence, incidence, death, and DALYs rates exhibited similar trends, increasing with age. From 1990 to 2021, both the prevalence and death rates showed a consistent downward trend across all age groups. Joinpoint regression analysis indicated a slight increase in both the ASPR (APC: 0.13; 95% CI: 0.06 to 0.19) and the ASIR (APC: 0.17; 95% CI: 0.10 to 0.24) during the period from 1990 to 1994. The leading DALYs attributable to risk factors for young COPD are household air pollution from solid fuels (20.4%), ambient particulate matter pollution (17.9%), and smoking (13.5%).ConclusionsThe global burden of ASPR, ASIR, ASDR, and age-standardised DALYs rates in young COPD has decreased, however, the absolute number of patients has increased. The global burden shows noticeable regional differences, with particularly high burdens observed in Oceania. Improving air quality, promoting smoking cessation, and increasing access to lung function tests, raising awareness of young COPD are key strategies for alleviating the burden of young COPD.

To comprehensively assess the global burden of syphilis and related risk factors over 1990-2021, forecast future disease trends, and understand the impact of syphilis on global health. Global Burden of Disease Study 2021 (GBD 2021) data were used for age-, sex-, and region-stratified analysis of the numbers and age-standardized rates (per 100,000 population) of syphilis incidence, prevalence, deaths, and disability-adjusted life years (DALYs). Next, a differential analysis of syphilis risk factors was performed. Finally, trends for years after 2021 were predicted using Bayesian age-period-cohort (BAPC) prediction models. In 2021, the total number of syphilis prevalence globally was 70,541,482.80 (95% uncertainty interval: 54,910,897.66-88,207,651.97), with the highest numbers noted in Central Sub-Saharan Africa [4,622.60 (95% uncertainty interval: 3,591.97-5,753.45)]. Over 1990-2021, the global age-standardized prevalence and incidence rates increased, whereas the age-standardized death and DALY rates decreased. Among all groups, infants aged <5 years demonstrated the highest age-standardized DALY rates. Moreover, the lower the sociodemographic index (SDI), the higher was the age-standardized rate. The primary factor contributing to syphilis disease burden was identified to be unsafe sex. BAPC analysis revealed an overall increase in age-standardized prevalence rate in the <5-year age group over 1990-2035, and the highest age-standardized prevalence rate occurred in the 25-34-year age group. Between 1990 and 2021, syphilis occurrence and prevalence increased consistently. Projections indicated a continual increase in syphilis incidence in children aged <5 years, and age-standardized prevalence rates were the highest in adults aged 25-34 years. Our results regarding the epidemiological trends of syphilis and its variations across regions, age groups, and sexes may aid policymakers in addressing the global impact of the disease effectively.

Objective: To assess the trends in the burden of periodontal disease among individuals aged 60 years and above in China from 1990 to 2021, thereby providing a scientific foundation for the development of targeted prevention and control strategies for periodontal disease in the elderly. Methods: Utilizing data from the Global Burden of Disease Study 2021 (GBD 2021), key indicators including incidence, prevalence, and disability-adjusted life years (DALY) rates were analyzed. Age-standardized rates were determined using the global standard population. Trends in the disease burden of periodontal disease among the elderly population in China from 1990 to 2021 were analyzed using Joinpoint regression analysis, and an autoregressive integrated moving average (ARIMA) model was applied to forecast the disease burden from 2022 to 2036. Results: The annual average percentage changes (AAPC) in the number of incident cases, prevalent cases, and DALYs due to periodontal disease among individuals aged 60 years and above in China from 1990 to 2021 were 3.215% (95%CI: 3.149%-3.281%, P<0.05), 3.161% (95%CI:3.037%-3.286%, P<0.05), and 3.091%(95%CI:2.887%-3.296%, P<0.05), respectively. The results indicated that the average annual change trends of the number of incident cases, number of prevalent cases, and number of DALYs were real upward trends. Compared with other age groups, the number of incident cases, prevalent cases, and DALYs were the highest among the population aged 60-69 years. The AAPC for age-standardized incidence rate, prevalence, and DALY rates were -0.012 (95%CI:-0.031%-0.008%, P>0.05), 0.023% (95%CI:-0.070%-0.116%, P>0.05), and 0.013% (95%CI:-0.089%-0.115%, P>0.05), respectively. This indicated that the average annual change trends of the age-standardized incidence rate, age-standardized prevalence rate, and age-standardized DALY rate might be caused by random fluctuations. Males exhibited higher prevalence and DALY rates than females across all age groups (P<0.05), whereas the incidence rates showed minimal differences between males and females across all age groups. The ARIMA forecast model indicated that the age-standardized incidence rate among males in the elderly population in China was relatively stable, while that among females showed a downward trend; the age-standardized prevalence and DALY rates followed a pattern of "decline-rise-decline". Conclusions: The disease burden of periodontal disease among Chinese adults aged 60 and above showed an overall upward trend from 1990 to 2021, with males and individuals aged 60-69 identified as high-risk groups. With the exacerbation of aging, the prevention and control situation remains severe, necessitating the implementation of gender-differentiated interventions to reduce the disease burden.

We estimated the global burden of ovarian cancer (OC) in 194 countries and territories between 2007 and 2017. Data were extracted from the Global Burden of Disease (GBD), Injuries, and Risk Factors 2017 study. Globally, 286 126.80 (95% UI=278 075.38-295 311.41) incident cases, 4.67 million (4.53-4.83) disability-adjusted life-years (DALYs), and 175 981.99 (171 384.15-181 198.43) deaths were reported in 2017. The age-standardized incidence and DALY rates increased by 2.05% and 1.34% during 2007-2017, respectively, while the age-standardized mortality rate decreased by -0.14%. The age-standardized incidence, DALY, and mortality rates in 2017 were the highest in the high socio-demographic index (SDI) quintile, but the largest percentage increase during 2007-2017 was in the low-SDI quintile. Among regions, Central Europe showed the highest 2017 age-standardized incidence, DALY, and mortality rates, whereas South Asia and East Asia showed the largest percentage increases in both rates during 2007-2017. Among countries, India showed the largest percentage increase in age-standardized incidence and DALY rates, whereas Iran showed the largest percentage increase in age-standardized mortality rates. Globally, the largest percentage increase in risk-attributable DALYs was associated with metabolic risk factors (e.g., high fasting plasma glucose levels). The global age-standardized incidence, DALYs, and mortality rates of OC remain stable during 2007-2017. However, the low SDI quintile and the greatest burden in South and East Asia, India, and Iran suggested that more targeted strategies should be performed in those regions and countries.

Acne vulgaris is a common skin condition affecting adolescents and young adults worldwide, yet data on the burden and trends of this disease remain limited. We aimed to investigate trends in the burden of acne vulgaris among adolescents and young adults aged 10-24 years at global, regional and national levels. We retrieved data from the Global Burden of Disease Study 2021 for individuals aged 10-24 years in 204 countries and territories from 1990 to 2021. We analysed the numbers, age-standardized rates and average annual percentage changes (AAPCs) of the prevalence, incidence and disability-adjusted life years (DALYs) for acne vulgaris at the global, regional and national levels. Additionally, we examined these global trends by age, sex and Sociodemographic Index (SDI). Globally, the age-standardized prevalence rate of acne vulgaris among adolescents and young adults increased from 8563.4 per 100 000 population [95% uncertainty interval (UI) 7343.5-9920.1] in 1990 to 9790.5 (95% UI 8420.9-11 287.2) per 100 000 population in 2021, with an AAPC of 0.43 [95% confidence interval (CI) 0.41-0.46]. The age-standardized incidence rate and age-standardized DALY rate also showed a similar upward trend. Regionally, Western Europe had the highest age-standardized prevalence, incidence and DALY rates, while North Africa and the Middle East had the largest increase in these rates. By SDI quintile, the high SDI region had the highest age-standardized prevalence, incidence and DALY rates from 1990 to 2021, whereas the low-middle SDI region had the lowest burden of acne vulgaris but experienced the most significant increase in these rates. Globally, the age-standardized prevalence rate of acne vulgaris in 2021 was approximately 25% higher in young women than in young men (10 911.8 per 100 000 population vs. 8727.8 per 100 000 population). Among all age groups, adolescents aged 15-19 years had the highest age-specific prevalence rate, while adolescents aged 10-14 years experienced the largest increase from 1990 to 2021 (AAPC 0.50, 95% CI 0.48-0.52). The burden of acne vulgaris among adolescents and young adults has continued to increase in nearly all countries since the 1990s. Managing this condition remains a significant challenge, necessitating more effective and targeted interventions to control the acne burden.

To investigate the global burden of visceral leishmaniasis (VL) from 1990 to 2021 and predict the trends in the burden of VL from 2022 to 2035, so as to provide insights into global VL prevention and control. The global age-standardized incidence, prevalence, mortality and disability-adjusted life years (DALYs) rates of VL and their 95% uncertainty intervals (UI) were captured from the Global Burden of Disease Study 2021 (GBD 2021) data resources. The trends in the global burden of VL were evaluated with average annual percent change (AAPC) and 95% confidence interval (CI) from 1990 to 2021, and gender-, age-, country-, geographical area- and socio-demographic index (SDI)-stratified burdens of VL were analyzed. The trends in the global burden of VL were projected with a Bayesian age-period-cohort (BAPC) model from 2022 to 2035, and the associations of age-standardized incidence, prevalence, mortality, and DALYs rates of VL with SDI levels were examined with a smoothing spline model. The global age-standardized incidence [AAPC = -0.25%, 95% CI: (-0.25%, -0.24%)], prevalence [AAPC = -0.06%, 95% CI: (-0.06%, -0.06%)], mortality [AAPC = -0.25%, 95% CI: (-0.25%, -0.24%)] and DALYs rates of VL [AAPC = -2.38%, 95% CI: (-2.44%, -2.33%)] all appeared a tendency towards a decline from 1990 to 2021, and the highest age-standardized incidence [2.55/105, 95% UI: (1.49/105, 4.07/105)], prevalence [0.64/105, 95% UI: (0.37/105, 1.02/105)], mortality [0.51/105, 95% UI: (0, 1.80/105)] and DALYs rates of VL [33.81/105, 95% UI: (0.06/105, 124.09/105)] were seen in tropical Latin America in 2021. The global age-standardized incidence and prevalence of VL were both higher among men [0.57/105, 95% UI: (0.45/105, 0.72/105); 0.14/105, 95% UI: (0.11/105, 0.18/105)] than among women [0.27/105, 95% UI: (0.21/105, 0.33/105); 0.06/105, 95% UI: (0.05/105, 0.08/105)], and the highest mortality of VL was found among children under 5 years of age [0.24/105, 95% UI: (0.08/105, 0.66/105)]. The age-standardized incidence (r = -0.483, P < 0.001), prevalence (r = -0.483, P < 0.001), mortality (r = -0.511, P < 0.001) and DALYs rates of VL (r = -0.514, P < 0.001) correlated negatively with SDI levels from 1990 to 2021. In addition, the global burden of VL was projected with the BAPC model to appear a tendency towards a decline from 2022 to 2035, and the age-standardized incidence, prevalence, mortality and DALYs rates were projected to be reduced to 0.11/105, 0.03/105, 0.02/105 and 1.44/105 in 2035, respectively. Although the global burden of VL appeared an overall tendency towards a decline from 1990 to 2021, the burden of VL showed a tendency towards a rise in Central Asia and western sub-Saharan African areas. The age-standardized incidence and prevalence rates of VL were relatively higher among men, and the age-standardized mortality of VL was relatively higher among children under 5 years of age. The global burden of VL was projected to continue to decline from 2022 to 2035.